Canaccord Genuity Maintains Buy on Verona Pharma, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Verona Pharma (NASDAQ:VRNA) and raises the price target from $35 to $37.
July 22, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Verona Pharma and raises the price target from $35 to $37.
The Buy rating and increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100